Skip to main content

Daiichi Sankyo

Daiichi Sankyo Company, Limited is a Japanese pharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative prescription medicines and oncology therapeutics worldwide. The company concentrates its operational drug discovery activities around primary therapeutic areas, with a specialized strategic focus on Oncology and Specialty Medicine. Its key commercial pharmaceutical portfolio features breakthrough antibody-drug conjugates (ADCs) such as Enhertu for HER2-positive cancers, alongside Lixiana (edoxaban) for stroke prevention and Prasugrel. Principal revenue drivers consist of global commercial sales of proprietary prescription pharmaceuticals, alongside high-margin licensing royalty revenues and profit-sharing milestone payments from global partners like AstraZeneca. Daiichi Sankyo serves broad global healthcare end markets encompassing oncology specialty clinics, hospital networks, retail pharmacy chains, healthcare providers, and patients across Japan, North America, and Europe. The corporation holds a leading global market position as a premier biopharmaceutical pioneer in antibody-drug conjugate technologies for targeted cancer treatment. Headquartered in Tokyo, Japan, the company's common stock is primary listed on the Tokyo Stock Exchange under the ticker code 4568.

68 of the funds FundTelligence covers report a position in Daiichi Sankyo.

Sector
Health Care
Country
Japan
Funds holding it
68
Exposure themes
Cancer, Treatment, Women's Health

Funds holding Daiichi Sankyo

Showing the 8 largest of 68 funds holding it.

Loading...